Emerging Markets, Acquisitions Prop Up Growth At Sanofi Aventis
Executive Summary
Sanofi Aventis reported second quarter net sales up 6.5 percent at constant exchange rates, despite the early impact of generic competition in Europe on the heart drug Plavix (clopidogrel), anti-hypertensive Avapro (irbesartan), and cancer drug Eloxatin (oxaliplatin)
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009
Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009
Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
Shantha's pipeline includes Rotavirus, conjugated typhoid and HPV vaccines.